Phase II trial of re-irradiation stereotactic body radiotherapy for painful spinal metastases
Japanese Journal of Clinical Oncology · 2026
DOI: 10.1093/jjco/hyaf215 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Japanese Journal of Clinical Oncology, 2026. Verfasst von Kei Ito und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkoma…. Hauptthemen laut MEDLINE: Spinal Neoplasms, Radiosurgery, Re-Irradiation, Cancer Pain. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Objective
To evaluate the palliative efficacy of re-irradiation stereotactic body radiotherapy (SBRT) for painful spinal metastases.
Methods
In this single-centre, single-arm, phase II study, patients with painful spinal metastases (pain score ≥2 on a 0–10 scale) from solid tumours were enrolled. Eligibility criteria included absence of epidural spinal cord compression, and irradiation history (excluding SBRT) with an interval of ≥3 months. The prescribed dose was 24 Gy in two fractions; the maximum spinal cord dose constraint was 12.2 Gy. The primary endpoint was the pain response rate at 6 months in evaluable patients.
Results
Among 35 spinal lesions in 34 patients registered between July 2019 and June 2024, 11 (31%) lesions were severely painful (score, 8–10), 16 (46%) were radioresistant, and 14 (40%) involved ≥3 consecutive vertebrae. The median prior equivalent dose in 2-Gy fractions (α/β = 10) was 33 (range, 23–70) Gy, and median interval between irradiations was 12 (range, 3–114) months. The median follow-up period was 9 (range, 2–51) months. Among evaluable patients, pain response was 84% at 3 months and 83% at 6 months, whereas complete response (CR) was 48% and 56%, respectively. In the intention-to-treat analysis, pain response was 60% at 3 months and 43% at 6 months, whereas CR was 34% and 29%, respectively. The 6-month local failure rate was 7%. Two (6%) patients experienced grade 3 toxicities.
Conclusions
Re-irradiation SBRT achieved substantial pain relief with acceptable toxicity, warranting larger randomized trials against conventional radiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo 113-8677, Japan.
- Department of Radiation Oncology, Miyagi Cancer Center, 47-1 Nodayama, Medeshima-Shiote, Natori-shi, Miyagi 981-1293, Japan.
- Department of Radiological Sciences, Komazawa University, 1-23-1 Komazawa, Setagaya, Tokyo 154-8525, Japan.
ORCID-Profile: Kei Ito
Zitieren
APA
Ito, K., Ogawa, H., Nakajima, Y., Taguchi, K., Suda, Y., & Murofushi, K. N. (2026). Phase II trial of re-irradiation stereotactic body radiotherapy for painful spinal metastases. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf215
Vancouver
Ito K, Ogawa H, Nakajima Y, Taguchi K, Suda Y, Murofushi KN. Phase II trial of re-irradiation stereotactic body radiotherapy for painful spinal metastases. Japanese Journal of Clinical Oncology. 2026. doi:10.1093/jjco/hyaf215
BibTeX
@article{Ito2026,
author = {Ito, Kei and Ogawa, Hiroaki and Nakajima, Yujiro and Taguchi, Kentaro and Suda, Yuhi and Murofushi, Keiko Nemoto},
title = {Phase II trial of re-irradiation stereotactic body radiotherapy for painful spinal metastases},
journal = {Japanese Journal of Clinical Oncology},
year = {2026},
doi = {10.1093/jjco/hyaf215}
}
EUVIMED